NCT04603495: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
- State
- Under way
- Phase
- Phase 3
- People
- 430 taking part
- Started
- 9 Apr 2021
- Primary completion
- 23 Aug 2023
- Arms
- Pelabresib + ruxolitinib
- Results
- Posted on the registry
- 26 Oct 2020: Trial registered
- 9 Apr 2021: Trial started
- 28 Oct 2024: Trial results posted